{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:41Z","timestamp":1786982381558,"version":"build-2736575974"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Open access funding provided by HEAL-Link Greece"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03342-0","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T07:14:09Z","timestamp":1760339649000},"page":"5896-5930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preservative-Free Gel-Formulated Glaucoma Therapies: Learning from the Past, Looking to the Future"],"prefix":"10.1007","volume":"42","author":[{"given":"Anastasios G.","family":"Konstas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Holl\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstadinos G.","family":"Boboridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"3342_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S2214-109X(20)30425-3","volume":"9","author":"R Bourne","year":"2021","unstructured":"Bourne R, Steinmetz JD, Flaxman S, et al. Trends in prevalence of blindness and distance and near vision impairment over 30\u00a0years: an analysis for the global burden of disease study. Lancet Glob Health. 2021;9:130\u201343.","journal-title":"Lancet Glob Health"},{"key":"3342_CR2","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern\u00ae. Ophthalmology. 2021;128:P71\u2013150.","journal-title":"Ophthalmology"},{"key":"3342_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41433-018-0227-8","volume":"33","author":"HA Quigley","year":"2019","unstructured":"Quigley HA. 21st century glaucoma care. Eye. 2019;33:254\u201360.","journal-title":"Eye"},{"key":"3342_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40265-017-0843-9","volume":"78","author":"G Holl\u00f3","year":"2018","unstructured":"Holl\u00f3 G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-free prostaglandin analogs and prostaglandin\/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78:39\u201364.","journal-title":"Drugs"},{"key":"3342_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2020.21899","volume":"325","author":"JD Stein","year":"2021","unstructured":"Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults-screening, diagnosis, and management: a review. JAMA. 2021;325:164\u201374.","journal-title":"JAMA"},{"key":"3342_CR6","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","volume":"53","author":"GF Schwartz","year":"2008","unstructured":"Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53:S57-68.","journal-title":"Surv Ophthalmol"},{"key":"3342_CR7","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","volume":"118","author":"B Sleath","year":"2011","unstructured":"Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118:2398\u2013402.","journal-title":"Ophthalmology"},{"key":"3342_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127:477\u201383.","journal-title":"Ophthalmology"},{"key":"3342_CR9","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s40123-023-00730-z","volume":"12","author":"L Quaranta","year":"2023","unstructured":"Quaranta L, Novella A, Tettamanti M, Pasina L, Weinreb RN, Nobili A. Adherence and persistence to medical therapy in glaucoma: an overview. Ophthalmol Ther. 2023;12:2227\u201340.","journal-title":"Ophthalmol Ther"},{"key":"3342_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajo.2016.12.002","volume":"176","author":"HS Barnebey","year":"2017","unstructured":"Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%\/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61\u20139.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR11","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","volume":"390","author":"JB Jonas","year":"2017","unstructured":"Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390:2183\u201393.","journal-title":"Lancet"},{"key":"3342_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/jop.2008.0072","volume":"25","author":"TJ Zimmerman","year":"2009","unstructured":"Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25:145\u201352.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/jop.2018.0134","volume":"35","author":"C Wolfram","year":"2019","unstructured":"Wolfram C, Stahlberg E, Pfeiffer N. Patient-reported nonadherence with glaucoma therapy. J Ocul Pharmacol Ther. 2019;35:223\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1477-7525-1-75","volume":"1","author":"J-P Nordmann","year":"2003","unstructured":"Nordmann J-P, Auzanneau N, Ricard S, Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003;1:75.","journal-title":"Health Qual Life Outcomes"},{"key":"3342_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"3342_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2024.08.001","volume":"34","author":"MY Kahook","year":"2024","unstructured":"Kahook MY, Rapuano CJ, Messmer EM, Radcliffe NM, Galor A, Baudouin C. Preservatives and ocular surface disease: a review. Ocul Surf. 2024;34:213\u201324.","journal-title":"Ocul Surf"},{"key":"3342_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/jop.2013.0174","volume":"30","author":"CA Rasmussen","year":"2014","unstructured":"Rasmussen CA, Kaufman PL, Kiland JA. Benzalkonium chloride and glaucoma. J Ocul Pharmacol Ther. 2014;30:163\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14740338.2021.1873947","volume":"20","author":"AG Konstas","year":"2021","unstructured":"Konstas AG, Labb\u00e9 A, Katsanos A, et al. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opin Drug Saf. 2021;20:453\u201366.","journal-title":"Expert Opin Drug Saf"},{"key":"3342_CR19","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1038\/s41433-023-02578-w","volume":"37","author":"A-G Konstas","year":"2023","unstructured":"Konstas A-G, Boboridis KG, Athanasopoulos GP, et al. Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease\u2014a randomized controlled trial. Eye. 2023;37:3666\u201374.","journal-title":"Eye"},{"key":"3342_CR20","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma. 5th ed. Br J Ophthalmol. 2021;105:1\u2013169.","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"3342_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ceo.13989","volume":"50","author":"RJ Casson","year":"2022","unstructured":"Casson RJ. Medical therapy for glaucoma: a review. Clin Exp Ophthalmol. 2022;50:198\u2013212.","journal-title":"Clin Exp Ophthalmol"},{"key":"3342_CR22","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","volume":"402","author":"H Jayaram","year":"2023","unstructured":"Jayaram H, Kolko M, Friedman DS, Gazzard G. Glaucoma: now and beyond. Lancet. 2023;402:1788\u2013801.","journal-title":"Lancet"},{"key":"3342_CR23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1080\/14740338.2020.1826928","volume":"19","author":"AG Konstas","year":"2020","unstructured":"Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf. 2020;19:1445\u201360.","journal-title":"Expert Opin Drug Saf"},{"key":"3342_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/17469899.2019.1570138","volume":"14","author":"VP Costa","year":"2019","unstructured":"Costa VP, Aung T, Konstas AG. Evolution of the treatment paradigm for maximum medical therapy in glaucoma. Expert Rev Ophthalmol. 2019;14:33\u201342.","journal-title":"Expert Rev Ophthalmol"},{"key":"3342_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1089\/jop.2012.0186","volume":"29","author":"L Quaranta","year":"2013","unstructured":"Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29:382\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6138132","volume":"2020","author":"B Cvenkel","year":"2020","unstructured":"Cvenkel B, Kolko M. Current medical therapy and future trends in the management of glaucoma treatment. J Ophthalmol. 2020;2020:1\u201314.","journal-title":"J Ophthalmol"},{"key":"3342_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12325-016-0302-0","volume":"33","author":"AGP Konstas","year":"2016","unstructured":"Konstas AGP, Quaranta L, Bozkurt B, et al. 24-h efficacy of glaucoma treatment options. Adv Ther. 2016;33:481\u2013517.","journal-title":"Adv Ther"},{"key":"3342_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0002-9394(02)01699-9","volume":"134","author":"PJ Lama","year":"2002","unstructured":"Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134:749\u201360.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR29","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","volume":"112","author":"DC Broadway","year":"1994","unstructured":"Broadway DC, Grierson I, O\u2019Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication: II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446\u201354.","journal-title":"Arch Ophthalmol"},{"key":"3342_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/IJG.0b013e31825af67d","volume":"22","author":"C Boimer","year":"2013","unstructured":"Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730\u20135.","journal-title":"J Glaucoma"},{"key":"3342_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/IJG.0b013e318264cd68","volume":"23","author":"R Batra","year":"2014","unstructured":"Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma. 2014;23:56\u201360.","journal-title":"J Glaucoma"},{"key":"3342_CR32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/IJG.0000000000001041","volume":"27","author":"P Dubrulle","year":"2018","unstructured":"Dubrulle P, Labb\u00e9 A, Brasnu E, et al. Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. J Glaucoma. 2018;27:1105\u201311.","journal-title":"J Glaucoma"},{"key":"3342_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.34172\/apb.2021.048","volume":"11","author":"M Peter","year":"2020","unstructured":"Peter M, Panonnummal R. A review on newer ocular drug delivery systems with an emphasis on glaucoma. Adv Pharm Bull. 2020;11:399\u2013413.","journal-title":"Adv Pharm Bull"},{"key":"3342_CR34","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17425247.2023.2219053","volume":"20","author":"ZK Al-Qaysi","year":"2023","unstructured":"Al-Qaysi ZK, Beadham IG, Schwikkard SL, Bear JC, Al-Kinani AA, Alany RG. Sustained release ocular drug delivery systems for glaucoma therapy. Expert Opin Drug Deliv. 2023;20:905\u201319.","journal-title":"Expert Opin Drug Deliv"},{"key":"3342_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1124\/jpet.119.256933","volume":"370","author":"V Gote","year":"2019","unstructured":"Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370:602\u201324.","journal-title":"J Pharmacol Exp Ther"},{"key":"3342_CR36","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ophtha.2024.03.012","volume":"131","author":"JS Steger","year":"2024","unstructured":"Steger JS, Durai I, Odayappan A, et al. An evaluation of the efficacy and safety of timolol maleate 0.5% microdrops administered with the nanodropper. Ophthalmology. 2024;131:1045\u201355.","journal-title":"Ophthalmology"},{"key":"3342_CR37","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0002-9394(86)90771-3","volume":"101","author":"CM Lederer","year":"1986","unstructured":"Lederer CM, Harold RE. Drop size of commercial glaucoma medications. Am J Ophthalmol. 1986;101:691\u20134.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.drudis.2012.10.005","volume":"18","author":"L Gan","year":"2013","unstructured":"Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18:290\u20137.","journal-title":"Drug Discov Today"},{"key":"3342_CR39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/gels7030130","volume":"7","author":"R Cassano","year":"2021","unstructured":"Cassano R, Di Gioia ML, Trombino S. Gel-based materials for ophthalmic drug delivery. Gels. 2021;7:130.","journal-title":"Gels"},{"key":"3342_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/pharmaceutics12010057","volume":"12","author":"S Trombino","year":"2020","unstructured":"Trombino S, Cassano R. Special issue on designing hydrogels for controlled drug delivery: guest editors\u2019 introduction. Pharmaceutics. 2020;12:57.","journal-title":"Pharmaceutics"},{"key":"3342_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1081\/DDC-120003445","volume":"28","author":"I Pal Kaur","year":"2002","unstructured":"Pal Kaur I, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28:473\u201393.","journal-title":"Drug Dev Ind Pharm"},{"key":"3342_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/bjo.86.2.181","volume":"86","author":"P Aragona","year":"2002","unstructured":"Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86:181\u20134.","journal-title":"Br J Ophthalmol"},{"key":"3342_CR43","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/polym10111221","volume":"10","author":"T Irimia","year":"2018","unstructured":"Irimia T, Ghica M, Popa L, Anu\u0163a V, Arsene A-L, Dinu-P\u00eervu C-E. Strategies for improving ocular drug bioavailability and corneal wound healing with chitosan-based delivery systems. Polymers. 2018;10:1221.","journal-title":"Polymers"},{"key":"3342_CR44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijpharm.2018.05.040","volume":"546","author":"MA Moustafa","year":"2018","unstructured":"Moustafa MA, El-Refaie WM, Elnaggar YSR, Abdallah OY. Gel in core carbosomes as novel ophthalmic vehicles with enhanced corneal permeation and residence. Int J Pharm. 2018;546:166\u201375.","journal-title":"Int J Pharm"},{"key":"3342_CR45","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/pharmaceutics16101325","volume":"16","author":"BR Giri","year":"2024","unstructured":"Giri BR, Jakka D, Sandoval MA, Kulkarni VR, Bao Q. Advancements in ocular therapy: a review of emerging drug delivery approaches and pharmaceutical technologies. Pharmaceutics. 2024;16:1325.","journal-title":"Pharmaceutics"},{"key":"3342_CR46","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1080\/21691401.2017.1368024","volume":"46","author":"M Zhu","year":"2018","unstructured":"Zhu M, Wang J, Li N. A novel thermo-sensitive hydrogel-based on poly (N-isopropylacrylamide)\/hyaluronic acid of ketoconazole for ophthalmic delivery. Artif Cells Nanomedicine Biotechnol. 2018;46:1282\u20137.","journal-title":"Artif Cells Nanomedicine Biotechnol"},{"key":"3342_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119184","volume":"578","author":"Y Wei","year":"2020","unstructured":"Wei Y, Li C, Zhu Q, Zhang X, Guan J, Mao S. Comparison of thermosensitive in situ gels and drug-resin complex for ocular drug delivery: in vitro drug release and in vivo tissue distribution. Int J Pharm. 2020;578:119184.","journal-title":"Int J Pharm"},{"key":"3342_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101575","volume":"56","author":"RN Wadetwar","year":"2020","unstructured":"Wadetwar RN, Agrawal AR, Kanojiya PS. In situ gel containing bimatoprost solid lipid nanoparticles for ocular delivery: in-vitro and ex-vivo evaluation. J Drug Deliv Sci Technol. 2020;56:101575.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3342_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1208\/s12249-019-1431-y","volume":"20","author":"M Kouchak","year":"2019","unstructured":"Kouchak M, Mahmoodzadeh M, Farrahi F. Designing of a pH-triggered Carbopol\u00ae\/HMPC in situ gel for ocular delivery of dorzolamide HCl: in vitro, in vivo, and ex vivo evaluation. AAPS PharmSciTech. 2019;20:210.","journal-title":"AAPS PharmSciTech"},{"key":"3342_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0378-5173(89)90305-0","volume":"57","author":"A Rozier","year":"1989","unstructured":"Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite\u00ae: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm. 1989;57:163\u20138.","journal-title":"Int J Pharm"},{"key":"3342_CR51","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.2147\/OPTH.S172822","volume":"12","author":"V Kozobolis","year":"2018","unstructured":"Kozobolis V, Konstantinidis A, Sideroudi H, Teus M. Efficacy of the travoprost\/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation. Clin Ophthalmol. 2018;12:2393\u20138.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR52","doi-asserted-by":"publisher","first-page":"7631","DOI":"10.1007\/s00289-023-05095-8","volume":"81","author":"D Karati","year":"2024","unstructured":"Karati D, Mukherjee S, Singh S, Prajapati BG, Basu B. Biopolymer-based nano-formulations for mitigation of ocular infections: a review. Polym Bull. 2024;81:7631\u201358.","journal-title":"Polym Bull"},{"key":"3342_CR53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s42269-023-01123-9","volume":"47","author":"S Paul","year":"2023","unstructured":"Paul S, Majumdar S, Chakraborty M. Revolutionizing ocular drug delivery: recent advancements in in situ gel technology. Bull Natl Res Cent. 2023;47:154.","journal-title":"Bull Natl Res Cent"},{"key":"3342_CR54","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/polym13101641","volume":"13","author":"M Rudko","year":"2021","unstructured":"Rudko M, Urbaniak T, Musia\u0142 W. Recent developments in ion-sensitive systems for pharmaceutical applications. Polymers. 2021;13:1641.","journal-title":"Polymers"},{"key":"3342_CR55","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/polym13081340","volume":"13","author":"M Pandey","year":"2021","unstructured":"Pandey M, Choudhury H, Binti Abd Aziz A, et al. Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery: recent progress and contemporary research. Polymers. 2021;13:1340.","journal-title":"Polymers"},{"key":"3342_CR56","first-page":"395","volume":"48","author":"EW Hansen","year":"1950","unstructured":"Hansen EW. Mucocutaneous eruptions, including conjunctiva, due to drug sensitivity. Trans Am Ophthalmol Soc. 1950;48:395\u2013421.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"3342_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/IIO.0000000000000232","volume":"58","author":"M Banitt","year":"2018","unstructured":"Banitt M, Jung H. Ocular surface disease in the glaucoma patient. Int Ophthalmol Clin. 2018;58:23\u201333.","journal-title":"Int Ophthalmol Clin"},{"key":"3342_CR58","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2147\/OPTH.S24410","volume":"5","author":"C Baudouin","year":"2011","unstructured":"Baudouin C, Pflugfelder SC. Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol. 2011;5:1575\u201383.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/112067210701700311","volume":"17","author":"N Jaenen","year":"2007","unstructured":"Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"3342_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350\u20135.","journal-title":"J Glaucoma"},{"key":"3342_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153:1-9.e2.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/00061198-200112000-00008","volume":"10","author":"GD Novack","year":"2001","unstructured":"Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J Glaucoma. 2001;10:483\u20136.","journal-title":"J Glaucoma"},{"key":"3342_CR63","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/BF02853166","volume":"18","author":"R Noecker","year":"2001","unstructured":"Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205\u201315.","journal-title":"Adv Ther"},{"key":"3342_CR64","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","volume":"27","author":"DA Ammar","year":"2010","unstructured":"Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27:837\u201345.","journal-title":"Adv Ther"},{"key":"3342_CR65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/108076803762718097","volume":"19","author":"T Mundorf","year":"2003","unstructured":"Mundorf T, Williams R, Whitcup S, Felix C, Batoosingh A. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19:37\u201344.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR66","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/jop.2006.22.267","volume":"22","author":"A Labb\u00e9","year":"2006","unstructured":"Labb\u00e9 A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther. 2006;22:267\u201378.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR67","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","volume":"17","author":"ME Stern","year":"1998","unstructured":"Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17:584\u20139.","journal-title":"Cornea"},{"key":"3342_CR68","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jtos.2013.07.003","volume":"11","author":"C Baudouin","year":"2013","unstructured":"Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11:246\u201358.","journal-title":"Ocul Surf"},{"key":"3342_CR69","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276\u201383.","journal-title":"Ocul Surf"},{"key":"3342_CR70","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/01.all.0000183112.86181.9e","volume":"5","author":"C Baudouin","year":"2005","unstructured":"Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5:459\u201363.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"3342_CR71","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/IJG.0000000000000495","volume":"25","author":"MC Mocan","year":"2016","unstructured":"Mocan MC, Uzunosmanoglu E, Kocabeyoglu S, Karakaya J, Irkec M. The association of chronic topical prostaglandin analog use with meibomian gland dysfunction. J Glaucoma. 2016;25:770\u20134.","journal-title":"J Glaucoma"},{"key":"3342_CR72","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12325-008-0078-y","volume":"25","author":"MY Kahook","year":"2008","unstructured":"Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther. 2008;25:743\u201351.","journal-title":"Adv Ther"},{"key":"3342_CR73","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","volume":"27","author":"MY Kahook","year":"2008","unstructured":"Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofzia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339\u201343.","journal-title":"Cornea"},{"key":"3342_CR74","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/00061198-200312000-00008","volume":"12","author":"T Ishibashi","year":"2003","unstructured":"Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486\u201390.","journal-title":"J Glaucoma"},{"key":"3342_CR75","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/112067210901900409","volume":"19","author":"GCM Rossi","year":"2009","unstructured":"Rossi GCM, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"3342_CR76","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1167\/iovs.08-2992","volume":"50","author":"A Pauly","year":"2009","unstructured":"Pauly A, Meloni M, Brignole-Baudouin F, Warnet J-M, Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Investig Opthalmol Vis Sci. 2009;50:1644\u201352.","journal-title":"Investig Opthalmol Vis Sci"},{"key":"3342_CR77","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/bjo.74.7.409","volume":"74","author":"SS Weissman","year":"1990","unstructured":"Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. Br J Ophthalmol. 1990;74:409\u201312.","journal-title":"Br J Ophthalmol"},{"key":"3342_CR78","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","volume":"86","author":"C Baudouin","year":"2008","unstructured":"Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol (Copenh). 2008;86:716\u201326.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"3342_CR79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/01676830903324284","volume":"29","author":"MB Kashkouli","year":"2010","unstructured":"Kashkouli MB, Pakdel F, Hashemi M, et al. Comparing anatomical pattern of topical anti-glaucoma medications associated lacrimal obstruction with a control group. Orbit. 2010;29:65\u20139.","journal-title":"Orbit"},{"key":"3342_CR80","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00417-003-0777-7","volume":"241","author":"P Hamard","year":"2003","unstructured":"Hamard P, Blondin C, Debbasch C, Warnet J-M, Baudouin C, Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003;241:1037\u201343.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3342_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-4835(89)90071-7","volume":"49","author":"JR Samples","year":"1989","unstructured":"Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on culture corneal endothelial and trabecular meshwork cells. Exp Eye Res. 1989;49:1\u201312.","journal-title":"Exp Eye Res"},{"key":"3342_CR82","first-page":"40","volume":"110","author":"C Baudouin","year":"2012","unstructured":"Baudouin C, Denoyer A, Desbenoit N, Hamm G, Grise A. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2012;110:40\u201363.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"3342_CR83","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/archopht.1994.01090230051020","volume":"112","author":"DC Broadway","year":"1994","unstructured":"Broadway DC, Grieson I, O\u2019Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication: I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437\u201345.","journal-title":"Arch Ophthalmol"},{"key":"3342_CR84","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.ophtha.2004.06.023","volume":"111","author":"C Baudouin","year":"2004","unstructured":"Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111:2186\u201392.","journal-title":"Ophthalmology"},{"key":"3342_CR85","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5301\/ejo.5000181","volume":"23","author":"C Baudouin","year":"2013","unstructured":"Baudouin C, Renard J-P, Nordmann J-P, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013;23:47\u201354.","journal-title":"Eur J Ophthalmol"},{"key":"3342_CR86","first-page":"186","volume":"22","author":"F Levrat","year":"1999","unstructured":"Levrat F, Pisella PJ, Baudouin C. Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe. J Fr Ophtalmol. 1999;22:186\u201391.","journal-title":"J Fr Ophtalmol"},{"key":"3342_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/bjo.82.1.39","volume":"82","author":"C Baudouin","year":"1998","unstructured":"Baudouin C, De Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82:39\u201342.","journal-title":"Br J Ophthalmol"},{"key":"3342_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12325-016-0448-9","volume":"34","author":"A-G Konstas","year":"2017","unstructured":"Konstas A-G, Boboridis KG, Kapis P, et al. 24-hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide\/timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapy. Adv Ther. 2017;34:221\u201335.","journal-title":"Adv Ther"},{"key":"3342_CR89","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","volume":"88","author":"H Uusitalo","year":"2010","unstructured":"Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol (Copenh). 2010;88:329\u201336.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"3342_CR90","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418\u201323.","journal-title":"Br J Ophthalmol"},{"key":"3342_CR91","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2165\/00002512-199202030-00005","volume":"2","author":"AMV Brooks","year":"1992","unstructured":"Brooks AMV, Gillies WE. Ocular beta-blockers in glaucoma management: clinical pharmacological aspects. Drugs Aging. 1992;2:208\u201321.","journal-title":"Drugs Aging"},{"key":"3342_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4146124","volume":"2019","author":"L Negri","year":"2019","unstructured":"Negri L, Ferreras A, Iester M. Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life. J Ophthalmol. 2019;2019:1\u201312.","journal-title":"J Ophthalmol"},{"key":"3342_CR93","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.1981.03310390060024","volume":"245","author":"RB Schoene","year":"1981","unstructured":"Schoene RB, Martin TR, Charan NB, French CL. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA. 1981;245:1460\u20131.","journal-title":"JAMA"},{"key":"3342_CR94","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12325-020-01525-5","volume":"38","author":"AG Konstas","year":"2021","unstructured":"Konstas AG, Schmetterer L, Katsanos A, et al. Dorzolamide\/timolol fixed combination: learning from the past and looking toward the future. Adv Ther. 2021;38:24\u201351.","journal-title":"Adv Ther"},{"key":"3342_CR95","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.2147\/OPTH.S76053","volume":"8","author":"N Radcliffe","year":"2014","unstructured":"Radcliffe N. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol. 2014;8:2541\u20139.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR96","doi-asserted-by":"crossref","unstructured":"Korte J-M, Kaila T, Saari MK. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002;240:430\u20135.","DOI":"10.1007\/s00417-002-0462-2"},{"key":"3342_CR97","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/archopht.1980.01020041030004","volume":"98","author":"DB Soll","year":"1980","unstructured":"Soll DB. Evaluation of timolol in chronic open-angle glaucoma: once a day vs twice a day. Arch Ophthalmol. 1980;98:2178\u201381.","journal-title":"Arch Ophthalmol"},{"key":"3342_CR98","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0161-6420(93)31496-X","volume":"100","author":"SL Letchinger","year":"1993","unstructured":"Letchinger SL, Frohlichstein D, Glieser DK, et al. Can the concentration of timolol or the frequency of its administration be reduced? Ophthalmology. 1993;100:1259\u201362.","journal-title":"Ophthalmology"},{"key":"3342_CR99","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0002-9394(02)01460-5","volume":"133","author":"AGP Konstas","year":"2002","unstructured":"Konstas AGP, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC. A comparison of once-daily morning vs evening dosing of concomitant latanoprost\/timolol. Am J Ophthalmol. 2002;133:753\u20137.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR100","doi-asserted-by":"crossref","unstructured":"Uusitalo H, Ni\u00f1o J, Tahvanainen K, et al. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand. 2005;83:723\u20138.","DOI":"10.1111\/j.1600-0420.2005.00562.x"},{"key":"3342_CR101","doi-asserted-by":"crossref","unstructured":"Uusitalo H, K\u00e4h\u00f6nen M, Ropo A, et al. Improved systemic safety and risk\u2013benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244:1491\u20136.","DOI":"10.1007\/s00417-006-0328-0"},{"key":"3342_CR102","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR103","unstructured":"Shedden AH. Timolol maleate in a gel forming solution: a novel formulation of timolol maleate. Chibret Int J Ophthalmol. 1994;10:32\u20136."},{"key":"3342_CR104","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S0149-2918(01)80048-5","volume":"23","author":"A Shedden","year":"2001","unstructured":"Shedden A, Laurence J, Tipping R. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther. 2001;23:440\u201350.","journal-title":"Clin Ther"},{"key":"3342_CR105","doi-asserted-by":"crossref","unstructured":"Konstas AGP, Mantziris DA, Maltezos AA, Cate E, Stewart WC. Comparison of 24\u00a0hour control with Timoptic\u00ae 0.5% and Timoptic-XE TM 0.5% in exfoliation and primary open-angle glaucoma. Acta Ophthalmol Scand. 1999;77:541\u20133.","DOI":"10.1034\/j.1600-0420.1999.770511.x"},{"key":"3342_CR106","doi-asserted-by":"crossref","unstructured":"Larsson L-I. Intraocular pressure over 24\u00a0hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001;108:1439\u201344.","DOI":"10.1016\/S0161-6420(01)00605-4"},{"key":"3342_CR107","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0002-9394(01)01181-3","volume":"132","author":"K Dickstein","year":"2001","unstructured":"Dickstein K, Hapnes R, Aarsland T. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol. 2001;132:626\u201332.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR108","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0002-9394(14)70432-5","volume":"121","author":"K Dickstein","year":"1996","unstructured":"Dickstein K, Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol. 1996;121:367\u201371.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR109","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00061198-199300230-00006","volume":"2","author":"J Laurence","year":"1993","unstructured":"Laurence J, Holder D, Vogel R, et al. A double-masked, placebo-controlled evaluation of timolol in a gel vehicle. J Glaucoma. 1993;2:177\u201382.","journal-title":"J Glaucoma"},{"key":"3342_CR110","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000310682","volume":"210","author":"H Mayer","year":"1996","unstructured":"Mayer H, Von Der Ohe N. Efficacy of a novel hydrogel formulation in human volunteers. Ophthalmologica. 1996;210:101\u20133.","journal-title":"Ophthalmologica"},{"key":"3342_CR111","doi-asserted-by":"crossref","unstructured":"Easty DL, Nemeth-Wasmer G, Vounatsos J, et al. Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol. 2006;90:574\u20138.","DOI":"10.1136\/bjo.2005.080424"},{"key":"3342_CR112","doi-asserted-by":"crossref","unstructured":"Cagini C, Di Pasquale G, Lupidi M, et al. Timolol 0.1% gel versus timolol 0.5% eyedrops in the prophylaxis of ocular hypertension after phacoemulsification surgery. Eur J Ophthalmol. 2014;24:857\u201361.","DOI":"10.5301\/ejo.5000472"},{"key":"3342_CR113","doi-asserted-by":"crossref","unstructured":"Pece A, Allegrini D, Montesano G, Dimastrogiovanni AF. Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study. Clin Ophthalmol. 2016;10:1131\u20138.","DOI":"10.2147\/OPTH.S106096"},{"key":"3342_CR114","doi-asserted-by":"crossref","unstructured":"Rouland J-F, Morel-Mandrino P, Elena P-P, Polzer H, Sunder Raj P. Timolol 0.1% gel (nyogel 0.1%\u00ae) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica. 2002;216:449\u201354.","DOI":"10.1159\/000067548"},{"key":"3342_CR115","doi-asserted-by":"crossref","unstructured":"Rolle T, Curto D, Alovisi C, Franzone M, Brogliatti B, Grignolo FM. Timogel\u00ae vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance. Eur J Ophthalmol. 2012;22:28\u201333.","DOI":"10.5301\/ejo.5000006"},{"key":"3342_CR116","doi-asserted-by":"crossref","unstructured":"Quaranta L, Katsanos A, Floriani I, Riva I, Russo A, Konstas AGP. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52:1552\u20137.","DOI":"10.1177\/0091270011420254"},{"key":"3342_CR117","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1089\/jop.2013.0216","volume":"30","author":"M Iester","year":"2014","unstructured":"Iester M, Telani S, Frezzotti P, et al. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers. J Ocul Pharmacol Ther. 2014;30:476\u201381.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR118","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41433-019-0633-6","volume":"34","author":"A Garg","year":"2020","unstructured":"Garg A, Gazzard G. Treatment choices for newly diagnosed primary open angle and ocular hypertension patients. Eye. 2020;34:60\u201371.","journal-title":"Eye"},{"key":"3342_CR119","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.4103\/IJO.IJO_2706_22","volume":"71","author":"S Subbulakshmi","year":"2023","unstructured":"Subbulakshmi S, Kavitha S, Venkatesh R. Prostaglandin analogs in ophthalmology. Indian J Ophthalmol. 2023;71:1768\u201376.","journal-title":"Indian J Ophthalmol"},{"key":"3342_CR120","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1167\/iovs.07-0080","volume":"48","author":"Z Wan","year":"2007","unstructured":"Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Opthalmol Vis Sci. 2007;48:4107\u201315.","journal-title":"Invest Opthalmol Vis Sci"},{"key":"3342_CR121","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1517\/14656560903292649","volume":"10","author":"AJ Patil","year":"2009","unstructured":"Patil AJ, Vajaranant TS, Edward DP. Bimatoprost \u2013 a review. Expert Opin Pharmacother. 2009;10:2759\u201368.","journal-title":"Expert Opin Pharmacother"},{"key":"3342_CR122","unstructured":"Huang AS, Zeppieri M, Meyer JJ. Bimatoprost Ophthalmic Solution. StatPearls. Treasure Island: StatPearls Publishing; 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576421\/. Accessed 2 May 2025."},{"key":"3342_CR123","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016597","volume":"98","author":"W Tang","year":"2019","unstructured":"Tang W, Zhang F, Liu K, Duan X. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis. Medicine (Baltimore). 2019;98:e16597.","journal-title":"Medicine (Baltimore)"},{"key":"3342_CR124","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma. Ophthalmology. 2016;123:129\u201340.","journal-title":"Ophthalmology"},{"key":"3342_CR125","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.clinthera.2008.04.006","volume":"30","author":"J-W Cheng","year":"2008","unstructured":"Cheng J-W, Wei R-L. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther. 2008;30:622\u201332.","journal-title":"Clin Ther"},{"key":"3342_CR126","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5586719","volume":"2021","author":"Z Cai","year":"2021","unstructured":"Cai Z, Cao M, Liu K, Duan X. Analysis of the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in the treatment of oag\/oht patients. J Ophthalmol. 2021;2021:5586719.","journal-title":"J Ophthalmol"},{"key":"3342_CR127","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/108076804773710786","volume":"20","author":"R Quinones","year":"2004","unstructured":"Quinones R, Severin T, Mundorf T. Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial. J Ocul Pharmacol Ther. 2004;20:115\u201322.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR128","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ophtha.2004.08.022","volume":"112","author":"AGP Konstas","year":"2005","unstructured":"Konstas AGP, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262\u20136.","journal-title":"Ophthalmology"},{"key":"3342_CR129","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1136\/bjophthalmol-2012-303040","volume":"97","author":"DG Day","year":"2013","unstructured":"Day DG, Walters TR, Schwartz GF, et al. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol. 2013;97:989\u201393.","journal-title":"Br J Ophthalmol"},{"key":"3342_CR130","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/OPTH.S103084","volume":"10","author":"LE Pillunat","year":"2016","unstructured":"Pillunat LE, Eschstruth P, H\u00e4semeyer S, et al. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. Clin Ophthalmol. 2016;10:1759\u201365.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR131","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00417-016-3299-9","volume":"254","author":"I Stalmans","year":"2016","unstructured":"Stalmans I, Oddone F, Cordeiro MF, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016;254:1151\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3342_CR132","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s40123-023-00797-8","volume":"12","author":"SG Moore","year":"2023","unstructured":"Moore SG, Richter G, Modjtahedi BS. Factors affecting glaucoma medication adherence and interventions to improve adherence: a narrative review. Ophthalmol Ther. 2023;12:2863\u201380.","journal-title":"Ophthalmol Ther"},{"key":"3342_CR133","unstructured":"Drug Approval Package. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022184_lumigan_toc.cfm. Accessed 2025 Jan 2."},{"key":"3342_CR134","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ajo.2009.12.003","volume":"149","author":"LJ Katz","year":"2010","unstructured":"Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149:661\u201371.","journal-title":"Am J Ophthalmol"},{"key":"3342_CR135","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/IJG.0000000000002371","volume":"33","author":"FJ Mu\u00f1oz-Negrete","year":"2024","unstructured":"Mu\u00f1oz-Negrete FJ, Topouzis F, Oddone F, et al. Preservative-free bimatoprost 0.01% ophthalmic gel for glaucoma therapy: a phase\u00a0III randomized controlled trial. J Glaucoma. 2024;33:422\u201330.","journal-title":"J Glaucoma"},{"key":"3342_CR136","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2147\/OPTH.S89904","volume":"2016","author":"A Stevens","year":"2016","unstructured":"Stevens A, Iliev M, De Jong L, Grobeiu I, Hommer A. A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2016;2016:635\u201341.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR137","first-page":"2097","volume":"2012","author":"DR Nixon","year":"2012","unstructured":"Nixon DR, Simonyi S, Bhogal M, et al. An observational study of bimatoprost 0.01% in treatment-naive patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial. Clin Ophthalmol. 2012;2012:2097\u2013103.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR138","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2147\/OPTH.S137537","volume":"11","author":"SS Deshpande","year":"2017","unstructured":"Deshpande SS, Sonty S, Ahmad A. Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01%\u2014an observational switch study. Clin Ophthalmol. 2017;11:1371\u20136.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR139","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12886-016-0338-6","volume":"16","author":"YY Chen","year":"2016","unstructured":"Chen YY, Wang T-H, Liu C, et al. Tolerability and efficacy of bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01% (APPEAL Taiwan) study. BMC Ophthalmol. 2016;16:162.","journal-title":"BMC Ophthalmol"},{"key":"3342_CR140","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jfo.2018.04.012","volume":"41","author":"S Lazreg","year":"2018","unstructured":"Lazreg S, Merad Z, Nouri MT, et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-na\u00efve patients and patients intolerant to other hypotensive medications. J Fr Ophtalmol. 2018;41:945\u201354.","journal-title":"J Fr Ophtalmol"},{"key":"3342_CR141","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1089\/jop.2024.0092","volume":"41","author":"C Erb","year":"2025","unstructured":"Erb C, Topouzis F, Jayaram H, et al. Preclinical and clinical pharmacokinetics of a new preservative-free bimatoprost 0.01% ophthalmic gel to treat glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2025;41:8\u201316.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR142","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1517\/14656566.5.4.909","volume":"5","author":"RM Feldman","year":"2004","unstructured":"Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004;5:909\u201321.","journal-title":"Expert Opin Pharmacother"},{"key":"3342_CR143","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/archopht.123.7.898","volume":"123","author":"AGP Konstas","year":"2005","unstructured":"Konstas AGP, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123:898\u2013902.","journal-title":"Arch Ophthalmol"},{"key":"3342_CR144","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ophtha.2003.05.019","volume":"111","author":"DH Shin","year":"2004","unstructured":"Shin DH, Feldman RM, Sheu W-P. Efficacy and safety of the fixed combinations latanoprost\/timolol versus dorzolamide\/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111:276\u201382.","journal-title":"Ophthalmology"},{"key":"3342_CR145","doi-asserted-by":"crossref","unstructured":"Hommer A, Ganfort\u00ae Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%\/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53\u201362.","DOI":"10.1177\/112067210701700436"},{"key":"3342_CR146","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/IJG.0b013e3181507313","volume":"17","author":"JD Brandt","year":"2008","unstructured":"Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I. Bimatoprost\/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17:211\u20136.","journal-title":"J Glaucoma"},{"key":"3342_CR147","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/IJG.0b013e3181bdb586","volume":"19","author":"RA Lewis","year":"2010","unstructured":"Lewis RA, Gross RL, Sall KN, Schiffman RM, Liu CC, Batoosingh AL. The safety and efficacy of bimatoprost\/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2010;19:424\u20136.","journal-title":"J Glaucoma"},{"key":"3342_CR148","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/bjophthalmol-2012-302843","volume":"97","author":"AGP Konstas","year":"2013","unstructured":"Konstas AGP, Holl\u00f3 G, Mikropoulos DG, et al. 24-hour efficacy of the bimatoprost\u2013timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma. Br J Ophthalmol. 2013;97:857\u201361.","journal-title":"Br J Ophthalmol"},{"key":"3342_CR149","volume":"2014","author":"M Michelessi","year":"2014","unstructured":"Michelessi M, Lindsley K, Yu T, Li T. Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysis. Cochrane Database Syst Rev. 2014;2014:CD011366.","journal-title":"Cochrane Database Syst Rev"},{"key":"3342_CR150","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/00055735-200404000-00013","volume":"15","author":"RD Fechtner","year":"2004","unstructured":"Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132\u20135.","journal-title":"Curr Opin Ophthalmol"},{"key":"3342_CR151","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/112067210701700436","volume":"17","author":"AL Robin","year":"2007","unstructured":"Robin AL. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%\/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:685\u20136 (author reply 686\u20137).","journal-title":"Eur J Ophthalmol"},{"key":"3342_CR152","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/jop.2010.0038","volume":"26","author":"A Paranhos","year":"2010","unstructured":"Paranhos A, Mendon\u00e7a M, Silva MJ, et al. Hyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapy. J Ocul Pharmacol Ther. 2010;26:611\u20135.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3342_CR153","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5301\/ejo.5000009","volume":"22","author":"F Aptel","year":"2012","unstructured":"Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22:5\u201318.","journal-title":"Eur J Ophthalmol"},{"key":"3342_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5301\/ejo.5000077","volume":"22","author":"AGP Konstas","year":"2012","unstructured":"Konstas AGP, Haidich A-B, Rossetti L, Webers C. Prostaglandin-timolol fixed combinations efficacy: myth or reality? Eur J Ophthalmol. 2012;22:1\u20134.","journal-title":"Eur J Ophthalmol"},{"key":"3342_CR155","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1185\/03007995.2015.1039504","volume":"31","author":"H Lou","year":"2015","unstructured":"Lou H, Wang H, Zong Y, Cheng J-W, Wei R-L. Efficacy and tolerability of prostaglandin\u2013timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015;31:1139\u201347.","journal-title":"Curr Med Res Opin"},{"key":"3342_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229682","volume":"15","author":"Y Xing","year":"2020","unstructured":"Xing Y, Zhu L, Zhang K, Huang S. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: a systematic review and meta-analysis. PLoS\u00a0One. 2020;15:e0229682.","journal-title":"PLoS\u00a0One"},{"key":"3342_CR157","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1471-2415-14-161","volume":"14","author":"A Garc\u00eda-L\u00f3pez","year":"2014","unstructured":"Garc\u00eda-L\u00f3pez A, Paczka JA, Jim\u00e9nez-Rom\u00e1n J, Hartleben C. Efficacy and tolerability of fixed-combination bimatoprost\/timolol versus fixed-combination dorzolamide\/brimonidine\/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BMC Ophthalmol. 2014;14:161.","journal-title":"BMC Ophthalmol"},{"key":"3342_CR158","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1136\/bjophthalmol-2013-304064","volume":"98","author":"I Goldberg","year":"2014","unstructured":"Goldberg I, Gil Pina R, Lanzagorta-Aresti A, Schiffman RM, Liu C, Bejanian M. Bimatoprost 0.03%\/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%\/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol. 2014;98:926\u201331.","journal-title":"Br J Ophthalmol"},{"key":"3342_CR159","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2147\/OPTH.S84163","volume":"31","author":"F Cordeiro","year":"2015","unstructured":"Cordeiro F, Goldberg I, Schiffman R, Bernstein P, Bejanian M. Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naive patients vs previously treated patients. Clin Ophthalmol. 2015;31:1605\u201311.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR160","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.2147\/OPTH.S106159","volume":"10","author":"S Pfennigsdorf","year":"2016","unstructured":"Pfennigsdorf S, Eschstruth P, H\u00e4semeyer S, et al. Preservative-free bimatoprost 0.03%\/timolol 0.5% fixed combination in patients with glaucoma in clinical practice. Clin Ophthalmol. 2016;10:1837\u201346.","journal-title":"Clin Ophthalmol"},{"key":"3342_CR161","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/03007995.2023.2197496","volume":"39","author":"E Mrukwa-Kominek","year":"2023","unstructured":"Mrukwa-Kominek E, Misiuk-Hojlo M, Csutak A, Stalmans I, Garhofer G. A randomized clinical trial comparing three fixed combinations of bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2023;39:775\u201383.","journal-title":"Curr Med Res Opin"},{"key":"3342_CR162","first-page":"1512","volume":"104","author":"A Hedengran","year":"2020","unstructured":"Hedengran A, Steensberg AT, Virgili G, Azuara-Blanco A, Kolko M. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104:1512\u20138.","journal-title":"Br J Ophthalmol"},{"key":"3342_CR163","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/IJG.0b013e3181fc8129","volume":"21","author":"M Aihara","year":"2012","unstructured":"Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60\u20134.","journal-title":"J Glaucoma"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03342-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03342-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03342-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:03:14Z","timestamp":1763136194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03342-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":163,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3342"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03342-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anastasios Georgios Konstas: research funding from Bayer, Omni Vision, Santen and Th\u00e9a; fees for consultancy and lectures with travel support from Esteve, Intermed, Santen, Th\u00e9a and Vianex. G\u00e1bor Holl\u00f3 has received fees from Th\u00e9a for consultancy, and fees from Santen for consultancy and lectures with travel support. Konstadinos G. Boboridis has received fees from Alpha Intes, Th\u00e9a, Bausch & Lomb and Santen for consultancy and lectures with travel support. Prof. Anastasios G. Konstas is an Editorial Board member of\n                      Advances in Therapy\n                      . He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable as this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}